The Readout Loud
216: VC malaise, FDA confusion, & yet another Alzheimer's debate
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Is the era of the unicorn over? What's gotten into the FDA? And will a NASH drug ever work? Our colleague Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. We also discuss an FDA plot twist for a novel ALS treatment, a second shot for a once-promising liver drug, and the latest in the Covid-19 pandemic.